Loading the records…
Loading the records…
The Colorectal Cancer Early Detection Act (S5287) was introduced in the Senate and referred to committee. As an authorization bill with no specific funding amount, it signals legislative intent to expand colorectal cancer screening coverage. Impact on healthcare companies is modest at this early stage, with diagnostic labs Quest Diagnostics ($DGX) and Labcorp ($LH) positioned for mild volume increases.
Key takeaways, market implications, full AI analysis, and connected signals are available to HillSignal members.
Already have an account? Log in
No immediate market impact from this early-stage bill. Diagnostic lab stocks $DGX and $LH have structural tailwinds from preventive screening expansion but face execution risk from legislative process. HCA's procedural volume gains are a small positive. Investors should monitor HELP Committee hearings as the next catalyst.
On August 6, 2026, Sen. Jon Ossoff (D-GA) introduced S5287, the Colorectal Cancer Early Detection Act, with Sen. Katie Britt (R-AL) as original cosponsor. The bill was read twice and referred to the Committee on Health, Education, Labor, and Pensions (HELP). It is in early legislative stages with no markup or passage yet.
No explicit funding amount is authorized or appropriated in the bill text available; as an authorization bill, it does not allocate specific dollars. Actual spending would require future appropriations. The legislative path includes committee hearings, markup, Senate floor vote, House passage, and presidential action — none guaranteed at this point.
The primary mechanism is likely to mandate coverage of colorectal cancer screening without cost-sharing under Medicare and potentially commercial insurance, expanding access and thereby utilization. This drives additional volume for diagnostic labs (Quest, Labcorp) performing FIT, stool DNA, and other screening tests, and for hospitals (HCA) performing colonoscopies. Insurers (UnitedHealthcare) face upfront cost increases offset by reduced late-stage cancer treatment spending.
Sponsorship by a junior Senator (Ossoff) with bipartisan cosponsor (Britt, R-AL) suggests moderate legislative momentum but no guarantee of passage. The HELP Committee will determine scheduling. No related bills, companion legislation, or executive actions are identified in the data, making convergence currently absent.
Cross-referenced against federal contracts, SEC insider filings & congressional trade disclosures
No confirming evidence found yet from contracts, insider trades, or congressional activity
What the bill does
CMS reimbursement for lab-based colorectal cancer screening tests (e.g., FIT, Cologuard-type tests); increased utilization from expanded coverage
Who must act
Clinical laboratories including Quest Diagnostics
What happens
Increased volume of colorectal cancer screening lab tests reimbursed by Medicare and commercial insurers
Stock impact
Quest Diagnostics processes large volume of colorectal cancer screening tests; estimated 5-10% volume increase for screening tests contributes modest revenue given lab testing is core business
What the bill does
Same as $DGX; CMS reimbursement for lab-based colorectal cancer screening tests
Who must act
Clinical laboratories including Labcorp
What happens
Same as $DGX; increased volume of colorectal cancer screening lab tests
Stock impact
Labcorp's testing volume for colorectal cancer screening sees increase; similar revenue impact as Quest given comparable market position
Matched on shared policy language across AI analyses, with ticker & timing weight
Executive orders & memoranda affecting the same sectors or companies
This executive order establishes a Women's Health Division within the NIH to coordinate and accelerate research on understudied women's health conditions, and creates a White House Women's Health Task Force to drive policy reforms and translation of research into clinical practice across federal agencies. It directs specific agencies to prioritize research, data collection, and translation into prevention, diagnosis, and treatment, with a focus on all life stages from infancy through aging.
This executive order directs the Secretaries of State, Labor, and Homeland Security to coordinate with Commerce, Education, and the SBA when processing H-1B petitions, and requires them to consider whether the employer has engaged in layoffs of similarly situated U.S. workers within the past year. It also orders the Labor Department to review past labor condition applications for potential enforcement actions against sponsoring employers, effectively tightening scrutiny on H-1B usage, especially by outsourcing firms.
This proclamation orders the Secretaries of War and Veterans Affairs to mandate rapid, ongoing digital sharing of military personnel and medical records, deploy AI-powered tools for benefits applications, and update existing IT contracts for interoperability. It also requires the Transition Assistance Program to connect separating service members to specific jobs or training programs before discharge.
Free — no credit card
HillSignal scores every Congressional bill, federal contract, and insider filing for market impact and emails you the high-conviction ones — free, no credit card.
Weekly digest — the congressional activity that actually moved markets that week, in plain English. Free, one email.
Free forever plan · No credit card · Unsubscribe in one click
Want the live terminal too? Create a free account →